{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:11:09Z","timestamp":1783642269659,"version":"3.55.0"},"reference-count":37,"publisher":"IMR Press","issue":"12","license":[{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"State Assignment","award":["FZWM-2024-0012"],"award-info":[{"award-number":["FZWM-2024-0012"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Biosci. (Landmark Ed)"],"abstract":"<jats:p>Background: Epidermal growth factor receptor 4 (ERBB4) and neuregulin 4 (NRG4) have been shown to reduce steatosis and prevent the development of non-alcoholic steatohepatitis in mouse models, but little to nothing is known about their role in non-alcoholic fatty liver disease (NAFLD) in humans. This study is the first to investigate the expression of ERBB4 and NRG4 mRNAs and their role in lipid metabolism in the livers of individuals with obesity, type 2 diabetes and biopsy-proven NAFLD. Methods: Liver biospecimens were obtained intraoperatively from 80 individuals. Quantitative reverse transcription polymerase chain reaction was used to measure the expression levels of mRNAs ERBB4 and NRG4, as well as key lipogenesis genes in the liver tissue of the donors. Histological analysis was conducted on liver biopsies from 36 subjects, and the levels of the examined transcripts were compared with the stage of NAFLD. Results: In individuals with elevated body mass index (BMI), ERBB4 and NRG4 levels decreased, while ACACA levels increased. A strong negative correlation was observed between NRG4 and ACACA levels. No deregulation of the analyzed transcripts was detected in NAFLD. Conclusions: The study demonstrates a decrease in ERBB4 and NRG4 mRNA expression in the livers of subjects with high BMI but not in those with NAFLD. The correlation of the studied transcripts with major lipogenesis genes was assessed, and on this basis a putative scheme for NRG4-mediated suppression of hepatic de novo lipogenesis was hypothesised, offering new research vectors in this field.<\/jats:p>","DOI":"10.31083\/j.fbl2912414","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T11:37:01Z","timestamp":1735558621000},"source":"Crossref","is-referenced-by-count":5,"title":["The Putative Antilipogenic Role of NRG4 and ERBB4: First Expression Study on Human Liver Samples"],"prefix":"10.31083","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4543-7850","authenticated-orcid":true,"given":"Maria","family":"Bograya","sequence":"first","affiliation":[{"name":"Center for Immunology and Cellular Biotechnology, Institute of Medicine and Life Sciences, Immanuel Kant Baltic Federal University, 236001 Kaliningrad, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4989-045X","authenticated-orcid":true,"given":"Maria","family":"Vulf","sequence":"first","affiliation":[{"name":"Center for Immunology and Cellular Biotechnology, Institute of Medicine and Life Sciences, Immanuel Kant Baltic Federal University, 236001 Kaliningrad, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2075-2261","authenticated-orcid":true,"given":"Anastasia","family":"Minchenko","sequence":"first","affiliation":[{"name":"Center for Immunology and Cellular Biotechnology, Institute of Medicine and Life Sciences, Immanuel Kant Baltic Federal University, 236001 Kaliningrad, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4646-3436","authenticated-orcid":true,"given":"Natalia","family":"Gazatova","sequence":"first","affiliation":[{"name":"Center for Immunology and Cellular Biotechnology, Institute of Medicine and Life Sciences, Immanuel Kant Baltic Federal University, 236001 Kaliningrad, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7859-7108","authenticated-orcid":true,"given":"Georgy","family":"Kuznetsov","sequence":"first","affiliation":[{"name":"Surgical Department, Regional Clinical Hospital Kaliningrad, 236035 Kaliningrad, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7468-4861","authenticated-orcid":true,"given":"Natalia","family":"Todosenko","sequence":"first","affiliation":[{"name":"Center for Immunology and Cellular Biotechnology, Institute of Medicine and Life Sciences, Immanuel Kant Baltic Federal University, 236001 Kaliningrad, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0938-8577","authenticated-orcid":true,"given":"Larisa","family":"Volkova","sequence":"first","affiliation":[{"name":"Medical Faculty, Moscow University for Industry and Finance \u201cSynergy\u201d, 125190 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Ivanov","sequence":"first","affiliation":[{"name":"Center for Immunology and Cellular Biotechnology, Institute of Medicine and Life Sciences, Immanuel Kant Baltic Federal University, 236001 Kaliningrad, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5231-6910","authenticated-orcid":true,"given":"Larisa","family":"Litvinova","sequence":"first","affiliation":[{"name":"Center for Immunology and Cellular Biotechnology, Institute of Medicine and Life Sciences, Immanuel Kant Baltic Federal University, 236001 Kaliningrad, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2024,12,11]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Teng ML, Ng CH, Huang DQ, Chan KE, Tan DJ, Lim WH, et al. Global incidence and prevalence of nonalcoholic fatty liver disease. Clinical and Molecular Hepatology. 2023; 29: S32\u2013S42.","DOI":"10.3350\/cmh.2022.0365."},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012; 142: 1592\u20131609.","DOI":"10.1053\/j.gastro.2012.04.001."},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Daher D, Dahan KSE, Singal AG. Non-alcoholic fatty liver disease-related hepatocellular carcinoma. Journal of Liver Cancer. 2023; 23: 127\u2013142.","DOI":"10.17998\/jlc.2022.12.30."},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Wang R, Yang F, Qing L, Huang R, Liu Q, Li X. Decreased serum neuregulin 4 levels associated with non-alcoholic fatty liver disease in children with obesity. Clinical Obesity. 2019; 9: e12289.","DOI":"10.1111\/cob.12289."},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Ma Y, Gao M, Liu D. Preventing High Fat Diet-induced Obesity and Improving Insulin Sensitivity through Neuregulin 4 Gene Transfer. Scientific Reports. 2016; 6: 26242.","DOI":"10.1038\/srep26242."},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Linggi B, Carpenter G. ErbB receptors: new insights on mechanisms and biology. Trends in Cell Biology. 2006; 16: 649\u2013656.","DOI":"10.1016\/j.tcb.2006.10.008."},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Scheving LA, Zhang X, Garcia OA, Wang RF, Stevenson MC, Threadgill DW, et al. Epidermal growth factor receptor plays a role in the regulation of liver and plasma lipid levels in adult male mice. American Journal of Physiology. Gastrointestinal and Liver Physiology. 2014; 306: G370\u2013G381.","DOI":"10.1152\/ajpgi.00116.2013."},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Bhushan B, Banerjee S, Paranjpe S, Koral K, Mars WM, Stoops JW, et al. Pharmacologic Inhibition of Epidermal Growth Factor Receptor Suppresses Nonalcoholic Fatty Liver Disease in a Murine Fast-Food Diet Model. Hepatology (Baltimore, Md.). 2019; 70: 1546\u20131563.","DOI":"10.1002\/hep.30696."},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Fuchs BC, Hoshida Y, Fujii T, Wei L, Yamada S, Lauwers GY, et al. Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatology (Baltimore, Md.). 2014; 59: 1577\u20131590.","DOI":"10.1002\/hep.26898."},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Paranjpe S, Bowen WC, Mars WM, Orr A, Haynes MM, DeFrances MC, et al. Combined systemic elimination of MET and epidermal growth factor receptor signaling completely abolishes liver regeneration and leads to liver decompensation. Hepatology (Baltimore, Md.). 2016; 64: 1711\u20131724.","DOI":"10.1002\/hep.28721."},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Muthuswamy SK, Gilman M, Brugge JS. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. Molecular and Cellular Biology. 1999; 19: 6845\u20136857.","DOI":"10.1128\/MCB.19.10.6845."},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Vulf M, Bograya M, Komar A, Khaziakhmatova O, Malashchenko V, Yurova K, et al. NGR4 and ERBB4 as Promising Diagnostic and Therapeutic Targets for Metabolic Disorders. Frontiers in Bioscience (Elite Edition). 2023; 15: 14.","DOI":"10.31083\/j.fbe1502014."},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Guo L, Zhang P, Chen Z, Xia H, Li S, Zhang Y, et al. Hepatic neuregulin 4 signaling defines an endocrine checkpoint for steatosis-to-NASH progression. The Journal of Clinical Investigation. 2017; 127: 4449\u20134461.","DOI":"10.1172\/JCI96324."},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Chen Z, Wang GX, Ma SL, Jung DY, Ha H, Altamimi T, et al. Nrg4 promotes fuel oxidation and a healthy adipokine profile to ameliorate diet-induced metabolic disorders. Molecular Metabolism. 2017; 6: 863\u2013872.","DOI":"10.1016\/j.molmet.2017.03.016."},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Zeng F, Wang Y, Kloepfer LA, Wang S, Harris RC. ErbB4 deletion predisposes to development of metabolic syndrome in mice. American Journal of Physiology. Endocrinology and Metabolism. 2018; 315: E583\u2013E593.","DOI":"10.1152\/ajpendo.00166.2018."},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Chen L, Xuan Y, Zhu Y, Wang J, Tian W, Yang X, et al. Adipocyte secreted NRG4 ameliorates age-associated metabolic dysfunction. Biochemical Pharmacology. 2024; 225: 116327.","DOI":"10.1016\/j.bcp.2024.116327."},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Li Y, Jin L, Jiang F, Yan J, Lu Y, Yang Q, et al. Mutations of NRG4 Contribute to the Pathogenesis of Nonalcoholic Fatty Liver Disease and Related Metabolic Disorders. Diabetes. 2021; 70: 2213\u20132224.","DOI":"10.2337\/db21-0064."},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Chiang KM, Chang HC, Yang HC, Chen CH, Chen HH, Lee WJ, et al. Genome-wide association study of morbid obesity in Han Chinese. BMC Genetics. 2019; 20: 97.","DOI":"10.1186\/s12863-019-0797-x."},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Hardy T, Wonders K, Younes R, Aithal G P, Aller R, Allison M, et al. The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. Contemporary Clinical Trials. 2020; 98; 106175.","DOI":"10.1016\/j.cct.2020.106175."},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (Baltimore, Md.). 2005; 41: 1313\u20131321.","DOI":"10.1002\/hep.20701."},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Knowlden JM, Jones HE, Barrow D, Gee JMW, Nicholson RI, Hutcheson IR. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib (\u2018Iressa\u2019) response and resistance. Breast Cancer Research and Treatment. 2008; 111: 79\u201391.","DOI":"10.1007\/s10549-007-9763-9."},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Hemi R, Yochananov Y, Barhod E, Kasher-Meron M, Karasik A, Tirosh A, et al. p38 mitogen-activated protein kinase-dependent transactivation of ErbB receptor family: a novel common mechanism for stress-induced IRS-1 serine phosphorylation and insulin resistance. Diabetes. 2011; 60: 1134\u20131145.","DOI":"10.2337\/db09-1323."},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Oh YS, Shin S, Lee YJ, Kim EH, Jun HS. Betacellulin-induced beta cell proliferation and regeneration is mediated by activation of ErbB-1 and ErbB-2 receptors. PloS One. 2011; 6: e23894.","DOI":"10.1371\/journal.pone.0023894."},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"De Munck TJI, Boesch M, Verhaegh P, Masclee AAM, Jonkers D, van Pelt JF, et al. Is there a role for neuregulin 4 in human nonalcoholic fatty liver disease? PloS One. 2021; 16: e0251822.","DOI":"10.1371\/journal.pone.0251822."},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Dai YN, Zhu JZ, Fang ZY, Zhao DJ, Wan XY, Zhu HT, et al. A case-control study: Association between serum neuregulin 4 level and non-alcoholic fatty liver disease. Metabolism: Clinical and Experimental. 2015; 64: 1667\u20131673.","DOI":"10.1016\/j.metabol.2015.08.013."},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Tutunchi H, Mobasseri M, Aghamohammadzadeh N, Hooshyar J, Naeini F, Najafipour F. Serum neuregulin 4 (NRG-4) level and non-alcoholic fatty liver disease (NAFLD): A case-control study. International Journal of Clinical Practice. 2021; 75: e14555.","DOI":"10.1111\/ijcp.14555."},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Tian Z, Wang X, Han T, Sun C. Selegiline ameliorated dyslipidemia and hepatic steatosis in high-fat diet mice. International Immunopharmacology. 2023; 117: 109901.","DOI":"10.1016\/j.intimp.2023.109901."},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S, et al. The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. Current Protocols in Bioinformatics. 2016; 54: 1.30.1\u20131.30.33.","DOI":"10.1002\/cpbi.5."},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Research. 2000; 28: 27\u201330.","DOI":"10.1093\/nar\/28.1.27."},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Fisher DE, Carr CS, Parent LA, Sharp PA. TFEB has DNA-binding and oligomerization properties of a unique helix-loop-helix\/leucine-zipper family. Genes & Development. 1991; 5: 2342\u20132352.","DOI":"10.1101\/gad.5.12a.2342."},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Tang Z, Sun C, Yan Y, Niu Z, Li Y, Xu X, et al. Aberrant elevation of FTO levels promotes liver steatosis by decreasing the m6A methylation and increasing the stability of SREBF1 and ChREBP mRNAs. Journal of Molecular Cell Biology. 2023; 14: mjac061.","DOI":"10.1093\/jmcb\/mjac061."},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Azzam SK, Alsafar H, Sajini AA. FTO m6A Demethylase in Obesity and Cancer: Implications and Underlying Molecular Mechanisms. International Journal of Molecular Sciences. 2022; 23: 3800.","DOI":"10.3390\/ijms23073800."},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Zhang S, Ren X, Zhang B, Lan T, Liu B. A Systematic Review of Statins for the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism of Action. Molecules (Basel, Switzerland). 2024; 29: 1859.","DOI":"10.3390\/molecules29081859."},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Cao S, Hu Y. Effects of serum irisin, neuregulin 4, and weight management on obese adolescent girls with polycystic ovary syndrome. Bioscience Reports. 2021; 41: BSR20211658.","DOI":"10.1042\/BSR20211658."},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Lonardo A, Mantovani A, Lugari S, Targher G. Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity. Annals of Hepatology. 2020; 19: 359\u2013366.","DOI":"10.1016\/j.aohep.2020.03.001."},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Cho HW, Chung W, Moon S, Ryu OH, Kim MK, Kang JG. Effect of Sarcopenia and Body Shape on Cardiovascular Disease According to Obesity Phenotypes. Diabetes & Metabolism Journal. 2021; 45: 209\u2013218.","DOI":"10.4093\/dmj.2019.0223."},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Tarantino G, Sinatti G, Citro V, Santini SJ, Balsano C. Sarcopenia, a condition shared by various diseases: can we alleviate or delay the progression? Internal and Emergency Medicine. 2023; 18: 1887\u20131895.","DOI":"10.1007\/s11739-023-03339-z."}],"container-title":["Frontiers in Bioscience-Landmark"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/29\/12\/10.31083\/j.fbl2912414","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T11:53:46Z","timestamp":1735559626000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/29\/12\/10.31083\/j.fbl2912414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,11]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024]]}},"alternative-id":["S2768-6701(24)01547-8"],"URL":"https:\/\/doi.org\/10.31083\/j.fbl2912414","relation":{},"ISSN":["2768-6701","2768-6698"],"issn-type":[{"value":"2768-6701","type":"print"},{"value":"2768-6698","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,11]]},"article-number":"414"}}